If you have read anything about epithalon (epitalon), you have probably met a number: a 28% reduction in deaths in elderly patients, followed over 12 years. It is the single most persuasive statistic in the entire longevity-peptide space, and it is quoted constantly on supplement pages and forums as proof that this tetrapeptide extends human life.

There is a problem with that. The trial behind the 28% did not test epithalon. It tested Epithalamin — a crude extract of ground-up bovine pineal glands. The two are related, but they are not the same substance, and the distinction is the single most useful thing an Australian reader can learn about this compound. This post is a myth-vs-evidence breakdown of what epithalon research has actually shown, what belongs to a different drug entirely, and where the compound sits with the TGA.

What is epithalon (epitalon)? And what is Epithalamin?

Epitalon is a synthetic tetrapeptide — four amino acids, Ala-Glu-Asp-Gly (AEDG). It has a defined sequence, so any competent lab can make an identical molecule. It was developed at the St Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson's group, and it was designed as a simplified analogue of an earlier product.

Epithalamin (also written epithalamine) is that earlier product: a polypeptide extract of bovine pineal glands. It is not a single molecule. It is a mixture whose composition is not tightly standardised, which means the contents plausibly vary from batch to batch and preparation to preparation — a limitation noted in the Alzheimer's Drug Discovery Foundation's Cognitive Vitality review of the pair.

Calling an extract's results "epithalon results" is the same logical move as citing a red wine trial as evidence for resveratrol capsules. The analogue was inspired by the extract. That does not make the extract's clinical record transferable.

The 28% figure: what the trial actually tested

The study is Korkushko, Khavinson, Shatilo and Antonyuk-Shcheglova, published in Bulletin of Experimental Biology and Medicine in 2006. It was a 12-year randomised clinical study in elderly patients with coronary disease and accelerated ageing of the cardiovascular system, all of whom received the same standard therapy. The reported outcome: after 12 years, deaths in the epithalamine group were 28% lower than in controls, with cardiovascular mortality roughly two-fold lower, alongside improved exercise tolerance and reduced "functional age".

Three things to hold in mind

  • It used the extract, not the tetrapeptide. Every appearance of this number under an epithalon heading is a substitution.
  • It is one group, one region, unreplicated. The evidence base for both compounds is essentially a single Russian research programme. No independent team anywhere has run a comparable mortality trial, in either substance, in the two decades since.
  • The published abstracts are thin. Group sizes are small — a related long-term follow-up reported by the same researchers involved roughly 79 elderly coronary patients (about 39 treated, 40 control), dosed in six courses over three years. Mortality is described as "significantly lower" without the numerical detail, confidence intervals or blinding description that a modern reader would expect. The English-language indexing of this literature is also inconsistent enough that matching a quoted result to the exact preparation tested takes real effort.

None of this means the findings are fabricated. It means they are unverified, and the honest description is "one group's long-term observational-quality data on a non-standardised bovine extract" — not "epithalon cuts mortality".

The melatonin claim inherits the same problem

Epithalon is marketed heavily for sleep and circadian rhythm, on the logic that it restores pineal melatonin output. Again, the cleanest human-adjacent signal belongs to the extract: Epithalamin has been reported to stimulate melatonin production in older adults with pineal dysfunction and in aged rats.

For synthetic epitalon, the preclinical picture is genuinely mixed. A 2025 review in the International Journal of Molecular Sciences summarises work showing effects on pinealocyte cultures — including on the pCREB transcription factor and the AANAT enzyme, both plausible levers on melatonin synthesis — while noting that epitalon failed to stimulate melatonin in rats yet was reported to raise it in older primates. That is a mechanism worth studying. It is not a demonstrated clinical sleep effect in humans, and no controlled human sleep trial of synthetic epitalon has been published.

The one independent human-cell replication — and its November correction

The most genuinely new development in epithalon research is not Russian. In 2025, a team at Brunel University London (Al-Dulaimi and colleagues) published in Biogerontology the first independent replication of telomere effects in human cells: dose-dependent telomere extension and telomerase upregulation in normal breast epithelial cells and fibroblasts.

Two caveats deserve equal billing with the headline.

First, the cancer cell lines also lengthened their telomeres, apparently through an alternative lengthening of telomeres (ALT) mechanism rather than telomerase. Telomere maintenance is exactly the capability that lets a malignant cell divide indefinitely. Whether that matters in a whole organism is unknown — but it is an open question, not a footnote, and nobody has answered it.

Second, a formal Correction was published on 15 November 2025, replacing Figures 1, 2 and 3 of the original paper, which had been published with the wrong figures. The corrected article's conclusions stand, and errata of this kind are routine housekeeping rather than misconduct. But it is a reminder that this is a single, very recent, dish-level study, and dish-level studies are the beginning of an evidence base, not the end of one.

For more background on how this compound is usually described versus what has been tested, see our epithalon profile and the wider peptides library.

Is epithalon legal in Australia? The TGA position

Epithalon is approved nowhere in the world as a medicine. It has no marketing authorisation in Australia, the United States, the EU or the UK, and it is not on the Australian Register of Therapeutic Goods (ARTG).

A common line online is that epithalon is "unscheduled, therefore legal". That misreads how the system works. The Poisons Standard governs how a scheduled substance is handled; it is not a list of approved medicines. A product supplied or advertised in Australia for a therapeutic purpose is a therapeutic good, and if it is not on the ARTG it has not been assessed by the TGA for safety, quality or efficacy — regardless of whether the active ingredient happens to appear by name in a schedule.

The TGA has been explicit about this space. It has announced a strengthened compliance focus on unapproved peptide products marketed for anti-ageing and performance, citing adverse-event reports and state hospitalisation data, and naming products containing BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as examples of unapproved goods. Its stated responses include infringement notices, product seizures, import interventions and civil or criminal penalties. The regulator has form here too: the Federal Court ordered Peptide Clinics Pty Ltd to pay $10 million for advertising breaches that included anti-ageing and insomnia claims.

Practical Australian reading: there is no lawful consumer supply channel for epithalon here, "research use only" labelling does not change what a product is, and imported vials of an unapproved good carry a real risk of interception. We do not tell readers where to buy anything — but we will tell you when a market exists mainly because a regulator has not caught up with it yet.

What would actually settle the question

Three things, none of which exist yet:

  1. An independent replication of the mortality claim using synthetic AEDG — not the bovine extract — with pre-registered endpoints.
  2. Human pharmacokinetics. A tetrapeptide injected subcutaneously faces the same basic problem as BPC-157: we have almost no published data on what plasma exposure looks like, how fast it is cleared, or whether it reaches the pineal gland at all.
  3. An oncology safety answer to the ALT finding in cancer lines, ideally in animal models carrying established tumours.

Until then, the accurate summary is: an interesting mechanism, one recent independent cell-culture replication, essentially one group's human data on a different preparation, and no approval anywhere.

Want the next update when a real trial registers or the Brunel line of work is extended? Join the free list — evidence-first, no hype, no product pitches.

FAQ

What is epithalon and how is it different from Epithalamin?

Epithalon (epitalon) is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly, with a defined structure. Epithalamin is an older, non-standardised extract of bovine pineal glands from which epitalon was derived — most of the famous human clinical results, including the 28% mortality figure, come from the extract, not the synthetic peptide.

Is epithalon legal in Australia?

Epithalon is not approved as a medicine anywhere and is not on the ARTG, so it cannot be lawfully supplied or advertised in Australia as a therapeutic good. The TGA has announced strengthened compliance action against unapproved peptide products, including seizures and import interventions.

Does epithalon lengthen telomeres in humans?

In human cells in a dish, yes — a 2025 Brunel University London study reported dose-dependent telomere extension in normal fibroblasts and breast epithelial cells. That is not the same as an effect in a living person, and the same study saw telomere lengthening in breast cancer lines, which remains an unresolved safety question.

Are there human clinical trials of epithalon?

There are no modern, independent, controlled human trials of synthetic epitalon. The long-term human data most often cited comes from a single Russian research programme using the bovine pineal extract Epithalamin, and has never been independently replicated.

Sources

This article is independent information, not medical advice. Epithalon (epitalon) is not approved as a medicine in Australia or any other country and is not on the ARTG; speak to a qualified Australian health professional before making any health decision.